Essential Drugs

What Essential Drugs does

Essential Drugs Company Limited (EDCL) is a 100% government-owned pharmaceutical manufacturer established in 1983 and operating under Bangladesh's Ministry of Health and Family Welfare. The company operates five manufacturing facilities — Dhaka (headquarters, multi-form), Bogura (solid dosage + 4th-generation cephalosporin at 1,800 vials/hour), Gopalganj 3rd Plant (contraceptives, IV fluids, penicillin), Khulna Essential Latex Plant (condoms at ~249.60 million pieces/year), and the Tangail latex processing unit — producing 150+ essential medicines including tablets, syrups, capsules, ointments, creams, SVP and LVP injections, and condoms. Technology is centered on cGMP-compliant manufacturing with multi-AHU HVAC zoning, negative-pressure rooms, European-origin WFI plants, in-house QA/QC laboratories (HPLC, GC, AAS, FTIR, stability chambers), and a Product Development Department handling formulation, analytical, validation, and regulatory functions.

EDCL's revenue model is institutional/government-channel driven. The company supplies subsidized essential medicines to Bangladesh's public healthcare infrastructure — government hospitals, medical college hospitals, civil surgeon offices, and community clinics — through Ministry of Health procurement, with pricing determined via government tender mechanisms rather than market price discovery. A secondary channel supplies pharmaceutical products to WHO, UNICEF, and the Social Marketing Company (SMC) through international competitive tenders, and exports are conducted to Sri Lanka, Bhutan, and additional countries. Customer concentration is effectively single-buyer: the Government of Bangladesh as dominant customer, supplemented by multilateral health agencies. Authorized capital stands at BDT 200 crore with paid-up capital of BDT 100.92 crore (shares at BDT 10 each), all held by the Government of Bangladesh, with FY2013-14 production value of BDT 426 crore the most recent disclosed scale benchmark.

The most significant strategic initiative is the Essential Biotech and Research Center at Gopalganj, a January 2024–December 2030 project backed by USD 250 million from the Asian Development Bank plus GoB and EDCL own funds, intended to establish Vaccines, Therapeutics, and Diagnostics (VTD) bio-manufacturing capability. The project roadmap targets fill-finish operations in 2027 and full bulk manufacturing in 2029, with technology transfer and regulatory qualification support from a coalition including WHO, UNICEF, GAVI, CEPI, and ADB. This positions EDCL to move beyond generic essential drugs into regulated bio-manufacturing for HPV, JE, TCV, COVID-19, cholera, and influenza vaccines, supported by a workforce of approximately 2,600 across all plants and facilities.

Name

Essential Drugs

Legal name

Essential Drugs Company Limited

Website

https://edcl.gov.bd

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

akta.pro secondary industries

Generic Tender & Government Supply Markets (HLAIABAM), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE)

Keywords

• Pharmaceutical manufacturing
• Essential medicines
• Government healthcare supply
• Vaccine production
• Contraceptive manufacturing

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Government Hospital and Health Facility Supply: EDCL manufactures essential medicines and supplies them to government hospitals, civil surgeon offices, and community clinics at subsidized prices. Revenue is generated through government procurement contracts and budgets allocated by the Ministry of Health and Family Welfare.
2. International Tenders (WHO, UNICEF, SMC): EDCL participates in international competitive bidding to supply pharmaceutical products to WHO, UNICEF, and the Social Marketing Company (SMC), generating foreign currency revenue.
3. Export to International Markets: Exports pharmaceutical products to Sri Lanka, Bhutan, and other countries, contributing to foreign exchange earnings.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Essential Drugs Company Limited (EDCL) manufactures and supplies over 150 essential pharmaceutical products, including tablets, syrups, capsules, ointments, creams, oral liquids, and 4th generation Cephalosporin injections, across cGMP-compliant plants in Dhaka, Bogura, and Gopalganj. The company also manufactures condoms at the Khulna Essential Latex Plant (~249.60 million pieces/year capacity) and is building a Vaccine, Therapeutics and Diagnostics bio-manufacturing facility at Gopalganj (2024-2030). All output is supplied to the Bangladesh government healthcare system at subsidized prices, with additional volumes sold through international tenders (WHO, UNICEF, SMC) and exports to Sri Lanka and Bhutan.

Product overview

Essential Drugs Company Limited (EDCL) is a 100% government-owned pharmaceutical manufacturing company under Bangladesh's Ministry of Health and Family Welfare. The company operates as a unified pharmaceutical portfolio with four main manufacturing plants: Dhaka Plant (solid, liquid, sterile SVP & LVP, powder for solution, ointments, creams), Bogura Plant (solid dosage forms), Gopalganj 3rd Plant (producing birth control injections, IV fluids, penicillin products, birth control pills), and Khulna Essential Latex Plant (condoms with ~249.60 million pieces/year capacity). The product portfolio includes over 150 essential medicines across tablets, syrups, capsules, ointments, and 4th generation Cephalosporin injections. A major new initiative is the Essential Biotech and Research Center in Gopalganj (2024-2030) for Vaccines, Therapeutics, and Diagnostics manufacturing. Products are supplied to government hospitals, civil surgeon offices, community clinics, and international organizations (WHO, UNICEF).

Differentiator

Problem solved

Functional benefit

Brands

• Essential Biotech and Research Center: A comprehensive vaccine, therapeutics and diagnostics (VTD) bio-manufacturing facility and research center being established in Gopalganj.

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor.

• WHO (World Health Organization)minorStrategic or Co-development PartnerWHO procures essential medicines from EDCL through international tender mechanisms. WHO is also part of the coalition supporting the vaccine project with technical advisory and guidance alongside UNICEF, GAVI, and CEPI.
• UNICEF BangladeshminorStrategic or Co-development PartnerUNICEF procures essential medicines from EDCL through international tender processes. UNICEF is part of the coalition providing technical advisory for the vaccine manufacturing project.
• Social Marketing Company (SMC)minorChannel Partner/ Reseller/ DistributorSMC is a social marketing organization that distributes EDCL's essential medicines and contraceptive products through their distribution network, particularly for family planning programs.
• GAVI, The Vaccine AllianceminorStrategic or Co-development PartnerGAVI is part of the coalition (alongside WHO, UNICEF, CEPI, and ADB) providing technical advisory and guidance for the vaccine manufacturing project, supporting technology transfer and regulatory approval processes.
• CEPI (Coalition for Epidemic Preparedness Innovations)minorStrategic or Co-development PartnerCEPI is part of the coalition providing technical advisory and guidance for the vaccine manufacturing project, particularly focused on pandemic preparedness and epidemic response capabilities.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Eskayef Pharmaceuticals (SK+F): Bangladeshi subsidiary of Sanofi with substantial generic pharma manufacturing, including injectables and biologics; comparable to EDCL on multi-dosage-form government supply model.
• ACI Limited: Diversified Bangladeshi conglomerate with a significant pharmaceuticals business producing generics and consumer health products; overlaps with EDCL on government tender supply.
• Square Pharmaceuticals: Largest Bangladeshi pharmaceutical manufacturer producing generics across all major dosage forms; competes directly with EDCL for Bangladesh government tenders and has a much larger export footprint across 40+ countries.
• Renata Limited: Bangladeshi pharmaceutical company producing animal health, human pharma, and contraceptives; competes with EDCL on oral contraceptives and essential generics for government supply.
• Beximco Pharmaceuticals: Major Bangladeshi generic pharma manufacturer with US FDA-approved facility and ARV leadership; competes with EDCL domestically and internationally on generic formulations and government tenders.
• Healthcare Pharmaceuticals: Bangladeshi pharma manufacturer producing generics across solid, liquid, and sterile forms for government and private markets; directly comparable to EDCL on essential medicine manufacturing.
• Incepta Pharmaceuticals: One of Bangladesh's largest pharmaceutical manufacturers producing 1,000+ generics, vaccines, and sterile injectables; directly comparable on multi-dosage-form manufacturing and government supply.

Broad incumbents

• HLL Lifecare Limited: Indian government-owned (Ministry of Health) contraceptives and healthcare products manufacturer; directly comparable to EDCL on state-owned pharma manufacturing and contraceptive supply to government family planning programs.

Emerging players

• Biological E. Limited: Indian vaccine and generic injectables manufacturer with WHO-PQ approved facilities; directly comparable to EDCL's planned vaccine and sterile injectable capabilities under the Gopalganj project.
• Serum Institute of India: World's largest vaccine manufacturer by doses; emerging peer for EDCL's Essential Biotech and Research Center vaccine project on global vaccine supply, WHO-PQ pathways, and ADB-aligned funding structures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Essential Drugs